178 related articles for article (PubMed ID: 36289130)
1. The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study.
Cox IA; de Graaff B; Ahmed H; Campbell J; Otahal P; Corte TJ; Moodley Y; Goh N; Hopkins P; Macansh S; Walters EH; Palmer AJ
Eur J Health Econ; 2023 Sep; 24(7):1121-1139. PubMed ID: 36289130
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.
Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H
Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632
[TBL] [Abstract][Full Text] [Related]
3. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G
Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447
[TBL] [Abstract][Full Text] [Related]
4. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia.
Cox IA; Otahal P; de Graaff B; Corte TJ; Moodley Y; Zappala C; Glaspole I; Hopkins P; Macansh S; Walters EH; Palmer AJ
Respirology; 2022 Mar; 27(3):209-216. PubMed ID: 34935240
[TBL] [Abstract][Full Text] [Related]
5. Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review.
Vaidya S; Hibbert CL; Kinter E; Boes S
Lung; 2017 Feb; 195(1):1-8. PubMed ID: 27866277
[TBL] [Abstract][Full Text] [Related]
6. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
Fan Y; Bender SD; Conoscenti CS; Davidson-Ray L; Cowper PA; Palmer SM; de Andrade JA;
Chest; 2020 Jun; 157(6):1522-1530. PubMed ID: 32004554
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).
Rodríguez-Nieto MJ; Cano-Jiménez E; Romero Ortiz AD; Villar A; Morros M; Ramon A; Armengol S
Pharmacoeconomics; 2023 Aug; 41(8):999-1010. PubMed ID: 37249823
[TBL] [Abstract][Full Text] [Related]
8. Burden of illness in progressive fibrosing interstitial lung disease.
Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
[No Abstract] [Full Text] [Related]
9. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
11. Health Care Costs at the End of Life for Patients with Idiopathic Pulmonary Fibrosis. Evaluation of a Pilot Multidisciplinary Collaborative Interstitial Lung Disease Clinic.
Kalluri M; Lu-Song J; Younus S; Nabipoor M; Richman-Eisenstat J; Ohinmaa A; Bakal JA
Ann Am Thorac Soc; 2020 Jun; 17(6):706-713. PubMed ID: 32197048
[No Abstract] [Full Text] [Related]
12. The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.
Cox IA; de Graaff B; Ahmed H; Campbell J; Otahal P; Corte TJ; Glaspole I; Moodley Y; Goh N; Macansh S; Walters EH; Palmer AJ
Qual Life Res; 2021 Sep; 30(9):2615-2632. PubMed ID: 33999322
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study.
Raimundo K; Chang E; Broder MS; Alexander K; Zazzali J; Swigris JJ
BMC Pulm Med; 2016 Jan; 16():2. PubMed ID: 26732054
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with hereditary haemochromatosis in Australia: a cost-of-illness study.
de Graaff B; Neil A; Sanderson K; Yee KC; Palmer AJ
Aust Health Rev; 2017 Jul; 41(3):254-267. PubMed ID: 27444148
[TBL] [Abstract][Full Text] [Related]
15. Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea.
Kim SW; Myong JP; Yoon HK; Koo JW; Kwon SS; Kim YH
Int J Tuberc Lung Dis; 2017 Feb; 21(2):230-235. PubMed ID: 28234090
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
Chuvarayan Y; Finger RP; Köberlein-Neu J
Eur J Health Econ; 2020 Feb; 21(1):115-127. PubMed ID: 31493181
[TBL] [Abstract][Full Text] [Related]
17. Unravelling the health and economic burden of interstitial lung diseases in adults in Australia.
Cox IA; de Graaff B; Zheng Q; Corte TJ; Haydn Walters E; Palmer AJ
Aust J Gen Pract; 2024 May; 53(5):333-336. PubMed ID: 38697068
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada.
Tarride JE; Hopkins RB; Burke N; Guertin JR; O'Reilly D; Fell CD; Dion G; Kolb M
Clinicoecon Outcomes Res; 2018; 10():127-137. PubMed ID: 29503576
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.
Morell F; Esser D; Lim J; Stowasser S; Villacampa A; Nieves D; Brosa M
BMC Pulm Med; 2016 Jan; 16():7. PubMed ID: 26758510
[TBL] [Abstract][Full Text] [Related]
20. The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.
Diamantopoulos A; Wright E; Vlahopoulou K; Cornic L; Schoof N; Maher TM
Pharmacoeconomics; 2018 Jul; 36(7):779-807. PubMed ID: 29492843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
